Archive for September, 2008
Latest Tactics to Stifle Generic Competition
In the last half of this decade, it is estimated that $100 billion worth of brand name drugs have lost (or will lose) patent exclusivity. Each year, generic drugs take more and more of the market share from brand-name drug manufacturers. In fact, the percentage of drug prescriptions dispensed for generics increased from 47% to [...]
Pharmaceutical Profile: Sequenom
I was reading my monthly copy of Pharmaceutical Executive magazine when I came across Joanna Breitstein’s excellent article profiling the latest trend in the pharmaceutical arena: big deals that are safe bets. In her article, “Place your Bets,” Breitstein characterizes Roche’s bid to acquire Genentech as a reflection of the cautious approach to deal-making that [...]
Bridion and the Tale of Two Agencies
Once upon a time, there was a promising new drug named Bridion. It was touted by its manufacturer as the first major pharmaceutical advance in the field of anesthesia in two decades. The drug was submitted to two powerful health authorities for marketing approval. Authorization looked like a foregone conclusion as advisory committees for both [...]
Speaking of Vaccinations…
In February, I posted an article about the increasing amounts of research being done with the Measles, Mumps and Rubella (MMR) vaccinations and how there is an increasing number of studies being done that disprove the vaccination’s link to autism. In it, I gave a little history on Andrew Wakefield, the British scientist who [...]
The New War on Drugs: Vaccinations?
Ask yourself, when your child grows up, do you want him to be a cocaine addict? What if there was something you could do to prevent it? What if it was as easy as protecting your child against tetanus or the mumps? We may not be far away from the first vaccine to fight against [...]
Loading ...